Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Major Depressive Disorder Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Major Depressive Disorder Overview | 13 | 1 |
| Pipeline Products for Major Depressive Disorder Comparative Analysis | 14 | 1 |
| Major Depressive Disorder Therapeutics under Development by Companies | 15 | 2 |
| Major Depressive Disorder Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Major Depressive Disorder Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Major Depressive Disorder Products under Development by Companies | 21 | 3 |
| Major Depressive Disorder Products under Investigation by Universities/Institutes | 24 | 1 |
| Major Depressive Disorder Companies Involved in Therapeutics Development | 25 | 36 |
| Aequus Pharmaceuticals Inc. | 25 | 1 |
| Alkermes Plc | 26 | 1 |
| Allergan Plc | 27 | 1 |
| Angelini Group | 28 | 1 |
| Avanir Pharmaceuticals, Inc. | 29 | 1 |
| Azevan Pharmaceuticals, Inc. | 30 | 1 |
| BioCrea GmbH | 31 | 1 |
| BioLite, Inc. | 32 | 1 |
| Bristol-Myers Squibb Company | 33 | 1 |
| Cerecor Inc. | 34 | 1 |
| Clera Inc. | 35 | 1 |
| Fabre-Kramer Pharmaceuticals, Inc. | 36 | 1 |
| GlaxoSmithKline Plc | 37 | 1 |
| H. Lundbeck A/S | 38 | 1 |
| Hua Medicine (Shanghai) Ltd. | 39 | 1 |
| Intra-Cellular Therapies, Inc. | 40 | 1 |
| Johnson &Johnson | 41 | 1 |
| Lead Discovery Center GmbH | 42 | 1 |
| Les Laboratoires Servier SAS | 43 | 1 |
| Luye Pharma Group Ltd. | 44 | 1 |
| Mapreg S.A.S. | 45 | 1 |
| Methylation Sciences Inc. | 46 | 1 |
| miCure Therapeutics Ltd. | 47 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 48 | 1 |
| Neuralstem, Inc. | 49 | 1 |
| nLife Therapeutics, S.L. | 50 | 1 |
| Otsuka Holdings Co., Ltd. | 51 | 1 |
| Pherin Pharmaceuticals, Inc. | 52 | 1 |
| Reviva Pharmaceuticals Inc. | 53 | 1 |
| Richter Gedeon Nyrt. | 54 | 1 |
| Saniona AB | 55 | 1 |
| Suven Life Sciences Ltd. | 56 | 1 |
| Takeda Pharmaceutical Company Limited | 57 | 1 |
| TRImaran Pharma, Inc. | 58 | 1 |
| Turing Pharmaceuticals AG | 59 | 1 |
| VistaGen Therapeutics , Inc. | 60 | 1 |
| Major Depressive Disorder Therapeutics Assessment | 61 | 13 |
| Assessment by Monotherapy Products | 61 | 1 |
| Assessment by Combination Products | 62 | 1 |
| Assessment by Target | 63 | 3 |
| Assessment by Mechanism of Action | 66 | 4 |
| Assessment by Route of Administration | 70 | 2 |
| Assessment by Molecule Type | 72 | 2 |
| Drug Profiles | 74 | 106 |
| (aripiprazole + sertraline hydrochloride) Drug Profile | 74 | 1 |
| (buprenorphine hydrochloride + samidorphan l-malate) Drug Profile | 75 | 5 |
| AAD-2004 Drug Profile | 80 | 1 |
| ALKS-7119 Drug Profile | 81 | 1 |
| AN-788 Drug Profile | 82 | 1 |
| apimostinel Drug Profile | 83 | 2 |
| aripiprazole Drug Profile | 85 | 2 |
| AV-101 Drug Profile | 87 | 3 |
| AVP-786 Drug Profile | 90 | 3 |
| BLI-1005 Drug Profile | 93 | 1 |
| brexpiprazole Drug Profile | 94 | 5 |
| bupropion hydrochloride ER Drug Profile | 99 | 1 |
| cariprazine Drug Profile | 100 | 5 |
| CB-2202 Drug Profile | 105 | 1 |
| CERC-301 Drug Profile | 106 | 2 |
| CERC-501 Drug Profile | 108 | 2 |
| CLR-3001 Drug Profile | 110 | 1 |
| D-473 Drug Profile | 111 | 1 |
| esketamine hydrochloride Drug Profile | 112 | 3 |
| FKB-01MD Drug Profile | 115 | 1 |
| gepirone hydrochloride ER Drug Profile | 116 | 2 |
| ITI-007 Drug Profile | 118 | 8 |
| JNJ-42847922 Drug Profile | 126 | 4 |
| JNJ-54175446 Drug Profile | 130 | 1 |
| ketamine hydrochloride Drug Profile | 131 | 1 |
| LY-03005 Drug Profile | 132 | 1 |
| MAP-4343 Drug Profile | 133 | 1 |
| MIN-117 Drug Profile | 134 | 2 |
| miR-135 Drug Profile | 136 | 1 |
| MSI-195 Drug Profile | 137 | 1 |
| NLF-NEU Drug Profile | 138 | 1 |
| NP-11948 Drug Profile | 139 | 1 |
| NSI-189 Drug Profile | 140 | 4 |
| onabotulinumtoxin A Drug Profile | 144 | 5 |
| PH-10 Drug Profile | 149 | 1 |
| rapastinel Drug Profile | 150 | 4 |
| RP-5063 Drug Profile | 154 | 2 |
| S-47445 Drug Profile | 156 | 1 |
| sirukumab Drug Profile | 157 | 4 |
| Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder Drug Profile | 161 | 1 |
| Small Molecule to Target SLC6A15 for Major Depressive Disorder and Anxiety Disorders Drug Profile | 162 | 1 |
| Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders Drug Profile | 163 | 1 |
| Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder Drug Profile | 164 | 1 |
| Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System Drug Profile | 165 | 1 |
| SRX-246 Drug Profile | 166 | 2 |
| SUVN-911 Drug Profile | 168 | 1 |
| TAK-653 Drug Profile | 169 | 1 |
| TGFK-07AD Drug Profile | 170 | 1 |
| trazodone hydrochloride Drug Profile | 171 | 2 |
| vortioxetine hydrobromide Drug Profile | 173 | 6 |
| VU-0431316 Drug Profile | 179 | 1 |
| Major Depressive Disorder Dormant Projects | 180 | 7 |
| Major Depressive Disorder Discontinued Products | 187 | 3 |
| Major Depressive Disorder Product Development Milestones | 190 | 10 |
| Featured News &Press Releases | 190 | 1 |
| Sep 26, 2016: Minerva Neurosciences Provides Update on MIN-117 Clinical Program | 190 | 1 |
| Sep 22, 2016: VistaGen Therapeutics Provides Business Outlook and Sets Corporate Milestones | 190 | 2 |
| Sep 21, 2016: Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder | 192 | 1 |
| Sep 21, 2016: Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder | 192 | 1 |
| Aug 16, 2016: Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide | 193 | 1 |
| Aug 05, 2016: Allergan and Richter Provide Update on Cariprazine Program | 193 | 1 |
| Jun 20, 2016: VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer | 194 | 2 |
| Jun 02, 2016: Trintellix (vortioxetine) Now Available in U.S. Pharmacies | 196 | 1 |
| Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202 | 196 | 1 |
| Jun 01, 2016: Minerva Neurosciences to Present data on MIN-117 | 196 | 1 |
| May 26, 2016: Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder | 196 | 1 |
| May 24, 2016: Alkermes to Present phase III Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting | 197 | 1 |
| May 20, 2016: Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent | 198 | 1 |
| May 16, 2016: Otsuka to Present Data on Brexpiprazole at American Psychiatric Association Annual Meeting | 198 | 1 |
| May 16, 2016: Turing Pharmaceuticals Announces FDA Acceptance of Second Investigational New Drug Application for TUR 002 (Intranasal Ketamine) | 199 | 1 |
| Appendix | 200 | 2 |
| Methodology | 200 | 1 |
| Coverage | 200 | 1 |
| Secondary Research | 200 | 1 |
| Primary Research | 200 | 1 |
| Expert Panel Validation | 200 | 1 |
| Contact Us | 200 | 1 |
| Disclaimer | 201 | 1 |